Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1Approved for marketing 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 1Expanded_access 1

Sponsor

Cancer Type

Dermatologic 8Thoracic 2Head & Neck 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 50Lung Neoplasms 13Neoplasms 8Melanoma 6Neoplasm Metastasis 5Head and Neck Neoplasms 5Squamous Cell Carcinoma of Head and Neck 4Breast Neoplasms 4Urinary Bladder Neoplasms 3Triple Negative Breast Neoplasms 3Stomach Neoplasms 3Ovarian Neoplasms 3Colorectal Neoplasms 3Carcinoma, Merkel Cell 3Carcinoma, Hepatocellular 3Uterine Cervical Neoplasms 2Prostatic Neoplasms 2Pancreatic Neoplasms 2Mesothelioma, Malignant 2Gastrointestinal Neoplasms 2Colonic Neoplasms 2Carcinoma, Squamous Cell 2Carcinoma, Renal Cell 2Carcinoma, Large Cell 2Carcinoma, Basal Cell 2Brain Neoplasms 2Advanced Non-Small Cell Lung Cancer 2Adenocarcinoma 2Vaccinia 1Uterine Neoplasms 1

Interventions

cemiplimab 2pembrolizumab 1Specimen Handling 1Nivolumab 1Magnetic Resonance Spectroscopy 1Interleukin-2 1Antineoplastic Protocols 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Carcinoma, Basal Cell × cemiplimab × Thoracic × Clear all
NCT04916002 2025-12-05

A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic Cancer

Regeneron Pharmaceuticals

Phase 2 Terminated
77 enrolled 18 charts
BreastDermatologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Basal Cell, Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Carcinoma, Merkel Cell, Triple Negative Breast Neoplasms

NCT06132191 2025-11-20

Expanded Access Use of Cemiplimab in Patients With Solid Tumors

Regeneron Pharmaceuticals

Approved for marketing
DermatologicThoracic

Carcinoma, Basal Cell, Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡